/ SOP DC0020.1
Hybridoma Development Initiation / Page 1 of 4 Version: 3
Effective Date: / September 14, 2016

Hybridoma Project Initiation Checklist

Date:
Company Name:
Primary Contact: / Secondary Contact:
Phone: / Fax: / Phone: / Fax:
E-mail: / E-mail:
Bill to: / Ship to:

Project Goals:

Please describe the overall goals for the antibodies you would like MBS to develop. Please include the attributes that you want the antibodies to have (for example, specificity) as well as the format(s) in which you plan to use the antibodies in your final application.
Do you have any information and/or past experience with raising an antibody response against this target?
 Yes  No
If YES, please describe:
Specify any known homology with endogenous mouse proteins:
Cross reactants of concern:

Reagent Information:

Please provide details for all possible immunogen and screening reagents available to support the project.

1 / Reagent: / Purpose: /  Immunogen  Screening  Other
Type of antigen:  Protein  Peptide  Carbohydrate  Other:
Description:  Purified  Lysate  Other: / % purity (method):
Origin of Molecule:  Human  Viral  Bacterial  Other: / Accession #
Expression System (if applicable): /  Bacterial Strain:
 Mammalian Cell Line:
 Other:
Amount available: / MW: / pI: / Storage:  -80C  -20C 4C
 Lyophilized / Reconstitution:
In Solution / Buffer: / Concentration:
2 / Reagent: / Purpose: /  Immunogen  Screening  Other
Type of antigen:  Protein  Peptide  Carbohydrate  Other:
Description:  Purified  Lysate  Other: / % purity (method):
Origin of Molecule:  Human  Viral  Bacterial  Other: / Accession #
Expression System (if applicable): /  Bacterial Strain:
 Mammalian Cell Line:
 Other:
Amount available: / MW: / pI: / Storage:  -80C  -20C 4C
 Lyophilized / Reconstitution:
In Solution / Buffer: / Concentration:
3 / Reagent: / Purpose: /  Immunogen  Screening  Other
Type of antigen:  Protein  Peptide  Carbohydrate  Other:
Description:  Purified  Lysate  Other: / % purity (method):
Origin of Molecule:  Human  Viral  Bacterial  Other: / Accession #
Expression System (if applicable): /  Bacterial Strain:
 Mammalian Cell Line:
 Other:
Amount available: / MW: / pI: / Storage:  -80C  -20C 4C
 Lyophilized / Reconstitution:
In Solution / Buffer: / Concentration:

Antibody Controls:

Please provide information about any positive control antibodies available to support the project.

1 / Antibody Description:
 Customer can provide
 Please order if needed - Supplier/Cat No:
Immunogen (if known):
Species source:  Mouse  Rabbit  Goat  Other:
Form:  Purified  Antiserum  Other:
Use information:
2 / Antibody Description:
 Customer can provide
 Please order if needed - Supplier/Cat No:
Immunogen (if known):
Species source:  Mouse  Rabbit  Goat  Other:
Form:  Purified  Antiserum  Other:
Use information:
Specify what types of samples you would like provided for internal evaluation:
 No internal work planned. All antibody samples remain at MBS for characterization and selection.
 Purified hybridoma fusion product samples, discovery-scale (0.5mg average yield)
 Corresponding set of antibody-biotin conjugates to support matched pair studies
 15mL overgrown supernatants from cryopreserved hybridoma fusion products
 3-5mL supernatants from cryopreserved hybridoma fusion products
Other:
Please describe any planned assay work with these samples:

MAINE BIOTECHNOLOGY SERVICES, INC.

1037R Forest Avenue Portland, Maine 04103 USA

800-925-9476 > 207-797-5454 > FAX: 207-797-5595

email:

/ SOP DC0020.1
Hybridoma Development Initiation / Page 1 of 4 Version: 3
Effective Date: / September 14, 2016

Hybridoma Development Timeline

Hybridoma Development Terms of Service

Maine Biotechnology Services offers over 25 years of hybridoma development and screening expertise. Our goal is to achieve the maximum level of satisfaction for all of our customers; however it is impossible to offer an absolute guarantee that we can develop a monoclonal antibody to every immunogen or meet the specific goals originally outlined. MBS guarantees that we keep our customers informed of project status and involve them at all critical points. In-process check points allow us to strategize with the customer when needed, increasing the chance for success. Customers have the ability to terminate the project at any point and will not be invoiced for work that was not performed.

Hybridoma development batch records are well maintained. All information and resulting product is confidential and the property of the customer.

Thank you for choosing MBS.

MBS Hybridoma Development Staff

Our experienced hybridoma development team will stay in contact with you throughout your project.

Contact / Position / E-mail / Phone Ext:
Carrie Rice / Director of Sales / / 14
Abby Culberson / Sales Account Manager / / 10
Jennifer Walker / Hybridoma Project Manager / / 27
Moira Reno / Lab Manager / / 24

MAINE BIOTECHNOLOGY SERVICES, INC.

1037R Forest Avenue Portland, Maine 04103 USA

800-925-9476 > 207-797-5454 > FAX: 207-797-5595

email: